First guidelines for unilateral cT1 renal tumor management

被引：1

作者：

Roos, Frederik C. ^{[1
]}

Thueroff, Joachim W. ^{[1
]}

机构：

[1] Johannes Gutenberg Univ Mainz, Dept Urol, D-55131 Mainz, Germany

来源：

NATURE REVIEWS UROLOGY | 2010年 / 7卷 / 03期

关键词：

CHRONIC KIDNEY-DISEASE; NEPHRECTOMY; MASSES;

D O I：

10.1038/nrurol.2010.22

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Current treatment options for clinical stage T1 renal tumors, in patients with a contralateral healthy kidney, are diverse. The first guidelines for the management of these lesions have recently been published, which state that tumor size and health status of the patient are important factors to consider. The inclusion of tumor location, patient age and major comorbidities might strengthen these guidelines in the future.

引用

页码：124 / 125

页数：3

共 50 条

[31] Clinical Outcomes of cT1 Micropapillary Bladder Cancer
Willis, Daniel L.
Fernandez, Mario I.
Dickstein, Rian J.
Parikh, Sahil
Shah, Jay B.
Pisters, Louis L.
Guo, Charles C.
Henderson, Samuel
Czerniak, Bogdan A.
Grossman, H. Barton
Dinney, Colin P.
Kamat, Ashish M.
JOURNAL OF UROLOGY, 2015, 193 (04): : 1129 - 1134
[32] Guideline Compliance Regarding Chest Imaging of Suspicious cT1 Renal Masses in MUSIC-KIDNEY
Semerjian, Alice
Ginsburg, Kevin
Qi, Ji
Johnson, Anna
Noyes, Sabrina
Rogers, Craig
Lane, Brian R.
UROLOGY PRACTICE, 2023, 10 (04) : 327 - 333
[33] CLINICAL IMPORTANCE AND PREDICTIVE FACTORS FOR PT3A UPSTAGING IN CT1 RENAL CELL CARCINOMA
de Marinho, Ana Catarina
Simoes, Pedro
Figueiredo, Arnaldo
JOURNAL OF UROLOGY, 2021, 206 : E1087 - E1087
[34] Predicting the risk of pT3a stage in cT1 clear cell renal cell carcinoma
Nocera, Luigi
Stolzenbach, Lara F.
Ruvolo, Claudia Colla
Wenzel, Mike
Tian, Zhe
Rosiello, Giuseppe
Bravi, Carlo A.
Candela, Luigi
Basile, Giuseppe
Larcher, Alessandro
Shariat, Shahrokh F.
Bertini, Roberto
Capitanio, Umberto
Salonia, Andrea
Montorsi, Francesco
Briganti, Alberto
Karakiewicz, Pierre I.
EJSO, 2021, 47 (05): : 1187 - 1190
[35] Phase II study of axitinib for downstaging cT2a to cT1 renal tumors for allowing partial nephrectomy (AXIPAN).
Patard, Jean-Jacques
Bernard, Jean-Christophe
Bensalah, Karim
Baumert, Herve
Lang, Herve
Jacqmin, Didier
Duclos, Brigitte
Ravaud, Alain
Laguerre, Brigitte
Albiges, Laurence
Arnoux, Armelle
Escudier, Bernard
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
[36] Photoelectrochemical properties of the CT1 dye: A DFT study
Camino, Bruno
De La Pierre, Marco
Ferrari, Anna Maria
JOURNAL OF MOLECULAR STRUCTURE, 2013, 1046 : 116 - 123
[37] RADICAL VERSUS PARTIAL NEPHRECTOMY FOR CT1 RENAL CELL CARCINOMA: A PROPENSITY-SCORE BASED ANALYSIS
Gershman, Boris
Thompson, R. Houston
Boorjian, Stephen
Lohse, Christine
Costello, Brian
Cheville, John
Leibovich, Bradley
JOURNAL OF UROLOGY, 2018, 199 (04): : E630 - E630
[38] Sentinel node biopsy for cT1 and cT2a gastric cancer
Park, DJ
Lee, HJ
Lee, HS
Kim, WH
Kim, HH
Lee, KU
Choe, KJ
Yang, HK
EJSO, 2006, 32 (01): : 48 - 54
[39] Evolution of renal function in patients with cT1 renal tumors after laparoscopic partial and radical nephrectomy. Predictive factors for renal function impairment
Luis Cardo, A.
Herranz Amo, F.
Rodriguez Cabero, M.
Hernandez Cavieres, J.
Subira Rios, D.
Moralejo Garate, M.
Aragon Chamizo, J.
Barbas Bernardos, G.
Ramirez Martin, D.
Hernandez Fernandez, C.
ACTAS UROLOGICAS ESPANOLAS, 2022, 46 (02): : 63 - 69
[40] THE RESULT OF PROTRACTED ARGININE SUPPLEMENTATION IN CT1 DEFICIENT PATIENTS
Leuzzi, V.
Casarano, Manuela
Chilosi, AnnaMaria
Battaglia, Francesca
Mancardi, Maria Margherita
Battini, Roberta
MOLECULAR GENETICS AND METABOLISM, 2009, 98 (1-2) : 89 - 89

← 1 2 3 4 5 →